GlassScriptPhysician profile
Jennifer R Murphy
NPI 1902316342
$2,821.16
in general payments reported to CMS, 2019-2025
23 companies · $452 in 2025
The $452 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $556 · 2022: $453 · 2023: $720 · 2024: $640 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $632.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $542.62 | 2022-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $344.95 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $254.18 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $200.84 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $92.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $89.69 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $77.12 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $68.14 | 2021 | |
| Corcept Therapeutics | $68.12 | 2025 | Korlym |
| Abbvie INC. | $55.55 | 2021 | |
| Smith+Nephew, INC. | $51.54 | 2022 | |
| Amgen INC. | $46.41 | 2021-2024 | Repatha |
| Irhythm Technologies, INC. | $43.67 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $43.15 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.48 | 2024-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $33.85 | 2024 | |
| Lilly USA, LLC | $32.38 | 2024-2025 | Mounjaro, Zepbound |
| Stryker Corporation | $27.75 | 2023 | 1788 |
| Ucb, INC. | $20.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $19.02 | 2022 | |
| Acorda Therapeutics, INC | $18.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.